Collectively, the data suggest that the absence of HTATIP2 expression promotes an aggressive tumor phenotype by enhancing the HIF2α-regulated β-catenin/c-Myc/MCL-1 signaling, increasing the susceptibility of tumors to sorafenib-activated EMT process, and improving tumor metabolic plasticity. Here, MCL1 is linked to neoplasm.